Novo Nordisk has entered a partnership with Vivtex to develop next generation oral biologic medicines for obesity and diabetes. The company has approved a €432 million investment to expand its oral ...

Novo Nordisk is expanding its tabletting facility in Monksland, Athlone, Ireland with a 432 million euro ($372.5 million) ...

Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss drugs is met.